相关实验视频

Updated: Jun 26, 2025

Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells

Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells

Published on: June 13, 2020

评估口服益生菌补充剂作为接受ICI的晚期肺癌患者的补充治疗:一个前性的现实世界研究

Liping Tong^1,2, Yuming Wan^1,2, Xiaoxiao Shi²

¹Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Cancer control : journal of the Moffitt Cancer Center

|May 13, 2024

概括

口服益生菌可以改善晚期小细胞肺癌 (SCLC) 患者的结果,这些患者接受免疫检查点抑制剂 (ICI) 治疗. 需要进一步的研究来确认SCLC和非小细胞肺癌 (NSCLC) 种群中的这些发现.

科学领域:

在瘤学瘤学.
微生物组研究微生物组研究
免疫治疗是一种免疫疗法.

背景情况:

晚期肺癌治疗通常涉及免疫检查点抑制剂 (ICI).
肠道微生物组在调节ICI疗效方面的作用是一个越来越感兴趣的领域.
口服益生菌正在研究作为一种潜在的辅助疗法,以提高ICI治疗结果.

研究的目的:

在接受ICI的晚期肺癌患者中评估口服益生菌补充剂的有效性.
评估口服益生菌对该患者群体无进展生存期 (PFS) 和客观反应率 (ORR) 的影响.

主要方法:

采用了前性,现实世界的研究设计.
接受ICI治疗的晚期肺癌患者被分为两组:一组接受口服益生菌 (OPS组) 和对照组 (C组).
主要终点是PFS;次要终点是ORR.

主要成果:

总共有253名患者被分析 (71名在OPS组,182名在C组).
在整体队列中没有观察到PFS中位数的显著差异.
在小细胞肺癌 (SCLC) 患者中,OPS组与C组相比,在小细胞肺癌 (SCLC) 患者中显著改善了PFS中位数 (11.1 vs 7.0个月,P = .049).
在OPS组非小细胞肺癌 (NSCLC) 队列中观察到改善中位PFS的趋势 (16.5与12.3个月,P = .56).

结论:

口服益生菌补充剂与ICI结合可能会改善晚期SCLC患者的治疗结果.
需要进一步的研究来验证这些发现,并探索NSCLC患者的潜在益处.
这项研究表明,益生菌在优化特定肺癌亚型的ICI治疗方面可能发挥作用.

关键词:

晚期的肺癌是一种癌症.免疫检查点抑制剂免疫检查点抑制剂口服益生菌是一种口服益生菌.现实世界的研究研究.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...